Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | thymidylate kinase, putative | 0.0358 | 0.5 | 0.5 |
Trypanosoma brucei | thymidylate kinase, putative | 0.0358 | 0.5 | 0.5 |
Onchocerca volvulus | Putative thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Loa Loa (eye worm) | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Trypanosoma cruzi | thymidylate kinase, putative | 0.0358 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Thymidylate kinase Tmk (dTMP kinase) (thymidylic acid kinase) (TMPK) | 0.0358 | 0.5 | 0.5 |
Plasmodium falciparum | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Toxoplasma gondii | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Treponema pallidum | thymidylate kinase (tmk) | 0.0358 | 0.5 | 0.5 |
Entamoeba histolytica | Thymidylate kinase, putative | 0.0358 | 0.5 | 0.5 |
Schistosoma mansoni | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Schistosoma mansoni | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Echinococcus granulosus | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Giardia lamblia | CDC8 | 0.0358 | 0.5 | 0.5 |
Plasmodium vivax | thymidylate kinase, putative | 0.0358 | 0.5 | 0.5 |
Trichomonas vaginalis | thymidylate kinase, putative | 0.0358 | 0.5 | 0.5 |
Mycobacterium leprae | probable thymidylate kinase Tmk (dTMP KINASE) (THYMIDYLIC ACID KINASE) (TMPK) | 0.0358 | 0.5 | 0.5 |
Mycobacterium ulcerans | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Leishmania major | thymidylate kinase-like protein | 0.0358 | 0.5 | 0.5 |
Trypanosoma brucei | thymidylate kinase, putative | 0.0358 | 0.5 | 0.5 |
Trichomonas vaginalis | thymidylate kinase, putative | 0.0358 | 0.5 | 0.5 |
Echinococcus multilocularis | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0358 | 0.5 | 0.5 |
Chlamydia trachomatis | thymidylate kinase | 0.0358 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 25 mg kg-1 | Tested for inhibition of pentylenetetrazole induced seizures in mice; Value is 1/16 of the LD50 range | ChEMBL. | 2170646 |
Activity (functional) | = 25 mg kg-1 | Tested for inhibition of pentylenetetrazole induced seizures in mice; Value is 1/16 of the LD50 range | ChEMBL. | 2170646 |
Damage score (functional) | = 0.33 | Tested for its effect on hippocampal neuronal damage in gerbils activity | ChEMBL. | 2170646 |
Damage score (functional) | = 2.64 | Tested for its effect on Hypoxia induced neuronal damage | ChEMBL. | 2170646 |
ED50 (functional) | ~ 51 mg kg-1 | Tested for inhibition of quinolinic-induced seizures in mice. | ChEMBL. | 2170646 |
ED50 (functional) | ~ 51 mg kg-1 | Tested for inhibition of quinolinic-induced seizures in mice. | ChEMBL. | 2170646 |
IC50 (binding) | > 100 uM | In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]-flunitrazepam | ChEMBL. | 2170646 |
IC50 (binding) | > 100 uM | Inhibition of [3H]-CPP binding to N-methyl-D-aspartate glutamate receptor of rat cortical or hippocampal membranes | ChEMBL. | 2170646 |
IC50 (binding) | > 100 uM | In vitro binding affinity for GABA-A receptor in rat cortical or hippocampal membranes using [3H]-flunitrazepam | ChEMBL. | 2170646 |
IC50 (binding) | > 100 uM | Inhibition of [3H]-CPP binding to N-methyl-D-aspartate glutamate receptor of rat cortical or hippocampal membranes | ChEMBL. | 2170646 |
LD50 (functional) | = 400 mg kg-1 | Tested for acute toxicity in mice after intraperitoneal administration; Value ranges from 200-400 mg/kg | ChEMBL. | 2170646 |
LD50 (functional) | = 400 mg kg-1 | Tested for acute toxicity in mice after intraperitoneal administration; Value ranges from 200-400 mg/kg | ChEMBL. | 2170646 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.